Patents Examined by Kagnew H. Gebreyesus
  • Patent number: 10655115
    Abstract: The invention relates to a polypeptide having hemicellulase activity which comprises the amino acid sequence set out in SEQ ID NO: 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 52, 57, 62, 67 or 72 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1, 6, 11, 16, 21, 26, 31, 36, 41, 46, 51, 56, 61, 66 or 71, SEQ ID NO: 4, 9, 14, 19, 24, 29, 34, 39, 44, 49, 54, 59, 64, 69 or 74, or a variant polypeptide or variant polynucleotide thereof, wherein the variant polypeptide has at least 75% sequence identity with the sequence set out in SEQ ID NO: 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 52, 57, 62, 67 or 72 or the variant polynucleotide encodes a polypeptide that has at least 75% sequence identity with the sequence set out in SEQ ID NO: 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 52, 57, 62, 67 or 72.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: May 19, 2020
    Assignee: DSM IP ASSETS B.V.
    Inventors: Alrik Pieter Los, Rene Marcel De Jong, Maaike Appeldoorn
  • Patent number: 10640759
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: May 5, 2020
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Patent number: 10633685
    Abstract: Methods for recombinant and enzymatic production of mogroside compounds and compositions containing mogroside compounds are provided by this invention.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: April 28, 2020
    Assignee: EVOLVA SA
    Inventors: Jens Houghton-Larsen, Katarzyna Krzystanek, Angelika Semmler, Iver Klavs Riishede Hansen, Soren Damkiaer, Yaoquan Liu, Jorgen Hansen, Sathish Kumar, Muthuswamy Panchapagesa Murali, Nina Nicoline Rasmussen
  • Patent number: 10633414
    Abstract: Methods of refolding proteins are provided, especially cysteine-containing proteins such as insulin, proinsulin, and analogues thereof. The methods make used of tandem folding via the addition, at two different time, of two different reducing agents. A first reversible reducing agent can be added to induce folding and, at a later time, a second irreversible reducing agent can be added to prevent and/or reverse the formation of aggregates via intermolecular sulfide bonds. The methods can be used to reform a variety of cysteine-containing proteins with high yield of the native form, e.g. about 60 mol %, 70 mol %, or more.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 28, 2020
    Assignee: Purdue Research Foundation
    Inventors: Nien-Hwa Linda Wang, Chongli Yuan, Morgan H. Crawford
  • Patent number: 10590454
    Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: March 17, 2020
    Assignee: Biogen MA Inc.
    Inventors: Rashmi Rohit Kshirsagar, Alan Gilbert
  • Patent number: 10577632
    Abstract: Disclosed are cell-free systems for metabolic engineering, methods for cell-free metabolic engineering, kits for preparing the disclosed systems, and kits for performing the disclosed methods. The disclosed systems, methods, and kits may be utilized to prepare a chemical product and to optimize conditions for preparing a chemical product. The disclosed systems, methods, and kits also may be utilized for combinatorial cell-free metabolism engineering.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: March 3, 2020
    Assignee: Northwestern University
    Inventors: Michael Christopher Jewett, Ashty Stephen Karim
  • Patent number: 10570425
    Abstract: The present invention provides an engineered cyanobacterium, comprising at least one plasmid selected from three novel pathways to produce acetate, which can convert atmospheric carbon dioxide as a raw material into acetate. The present invention also constructs the expression plasmid for three different transporters specific to acetate to be expressed in cyanobacteria, which comprises putative ABC transporter (AatA), succinate/acetate: proton symporter (SatP) and acetate/glycolate: cation symporter (ActP). Therefore, the engineered cyanobacteria of the present invention can produce 0.58 mg/L to 3.54 mg/L of acetate per hour.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: February 25, 2020
    Assignees: NATIONAL TSING HUA UNIVERSITY, CHANG CHUN PLASTICS CO., LTD., CHANG CHUN PETROCHEMICAL CO., LTD.
    Inventors: Roa-Pu Shen, Wei Lu
  • Patent number: 10570163
    Abstract: Disclosed are steviol glycosides referred to as rebaudioside V and rebaudioside W. Also disclosed are methods for producing rebaudioside M (Reb M), rebausoside G (Reb G), rebaudioside KA (Reb KA), rebaudioside V (Reb V) and rebaudioside (Reb W).
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: February 25, 2020
    Assignee: Conagen Inc.
    Inventors: Guohong Mao, Xiaodan Yu
  • Patent number: 10570433
    Abstract: The present invention relates to enzyme compositions and processes of producing and using the compositions for the saccharification of lignocellulosic material.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: February 25, 2020
    Assignee: Novozymes A/S
    Inventors: Jeffrey Shasky, Debbie Yaver, Donna Moyer
  • Patent number: 10563181
    Abstract: The present invention relates to the cloning and expression of cDNA encoding O-methyl transferase for catalyzing the synthesis of vital volatile flavor compounds such as mesifuran and vanillin, thereby playing a significant role in flavor biochemistry of mango. The present invention also provide a process for the preparation of volatile compounds by mesifuran, ferulic acid, guaiacol and vanillin, specifically mesifuran and vanillin using cDNA sequence.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 18, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Vidya Shrikant Gupta, Hemangi Girish Chidley, Ashish Balwant Deshpande, Ashok Prabhakar Giri
  • Patent number: 10563192
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 18, 2020
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Patent number: 10557161
    Abstract: The present invention is directed to isolated recombinant human ADA2 proteins, ADA2 biologically active fragments, and ADA2 fusion proteins. The proteins of the invention can be surprisingly used to restore ADA2 activity in subjects having loss-of-function mutations in ADA2 and increase differentiation of monocytes into macrophages, e.g., M2 macrophages, e.g., M2c macrophages, stimulate CD4+ T cell proliferation, and increase endothelial cell development. More specifically, the ADA2 proteins, ADA2 biologically active fragments, and ADA2 fusion proteins of the invention can be used to treat subjects having ADA2-associated diseases or disorders, including but not limited to, polyarteritis nodosa, Sneddon Syndrome, vasculitis, ischemic stroke, hemorrhagic stroke, lacunar stroke, aneurysm in the celiac artery, skin rash, skin necrosis, livedo racemosa, hepatosplenomegaly, organ failure, retinal artery occlusion, optic nerve atrophy, diplopia, cranial nerve palsy, strabismus, and low serum IgM.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: February 11, 2020
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Anthony Quinn, Zhinan Xia, Markley C. Leavitt, Mohammed Qatanani, Changlin Li, Gary Kachun Yiu
  • Patent number: 10556930
    Abstract: The present disclosure is generally related to transformed host cells and their use for the production of branched-chain acyl-ACPs, branched-chain acyl-ACP-derived chemicals and fuels, branched-chain fatty acids and producing branched-chain fatty acid-derived chemicals and fuels. More particularly, disclosed herein are transformed host cells and methods for producing branched-chain acyl-ACPs and branched-chain fatty acids in high titer and high percentages. Also disclosed are methods for producing specific branched-chain fatty acid species and producing branched-chain fatty acid-derived chemicals and fuels such as, for example, branched-chain alcohols and branched-chain fatty acid ethyl esters.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: February 11, 2020
    Assignee: Washington University
    Inventors: Fuzhong Zhang, Wen Jiang, Gayle Bentley
  • Patent number: 10544407
    Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: January 28, 2020
    Assignee: The Rockefeller University
    Inventors: Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
  • Patent number: 10544438
    Abstract: The present invention relates to a composition for preparing tagatose, wherein the composition is used for preparing tagatose from fructose and contains a protein including any one amino acid sequence of SEQ ID NOS: 1 to 7 or a microorganism expressing the protein. In addition, the present invention relates to a method for preparing tagatose from fructose, the method comprising a step of allowing the composition to react with fructose.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: January 28, 2020
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Yang Hee Kim, Sung Jae Yang, Young Mi Lee, Il Hyang Park, Seong Bo Kim, Hyun Kug Cho, Seung Won Park
  • Patent number: 10538789
    Abstract: This document describes biochemical pathways for producing isoprene by forming two vinyl groups in a central precursor produced from isobutyryl-CoA, 3-methyl-2-oxopentanoate, or 4-methyl-2-oxopentanoate as well as recombinant hosts for producing isoprene.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: January 21, 2020
    Assignee: INVISTA NORTH AMERICA S.A.R.L.
    Inventors: Mariusz Kamionka, Jan Modregger, Axel Niebisch, Alex Van Eck Conradie, Adriana Leonora Botes
  • Patent number: 10538787
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases. Also described are methods of making and using compositions comprising these linkers.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: January 21, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: David Paschon, Lei Zhang
  • Patent number: 10533181
    Abstract: The present invention relates to a yeast cell, in particular a recombinant yeast cell, the cell lacking enzymatic activity needed for the NADH-dependent glycerol synthesis or the cell having a reduced enzymatic activity with respect to the NADH-dependent glycerol synthesis compared to its corresponding wild-type yeast cell, the cell comprising one or more heterologous nucleic acid sequences encoding an NAD+-dependent acetylating acetaldehyde dehydrogenase (EC 1.2.1.10) activity. The invention further relates to the use of a cell according to the invention in the preparation of ethanol.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: January 14, 2020
    Assignee: DSM IP ASSETS B.V.
    Inventors: Jacobus Thomas Pronk, Antonius Jeroen Adriaan Van Maris, Victor Gabriel Guadalupe Medina
  • Patent number: 10533232
    Abstract: It relates to ?-3 fatty acid desaturase for the synthesis of pufas from Phytophthora parasitica, a plasmid containing the same, a recombinant microorganism containing the plasmid and its application. The invention also provides the use of the above ?-3 fatty acid desaturase in the biosynthesis of PUFAs, especially to catalyze C20:4?5,8,11,14 to C20:5?5,8,11,14,17 at normal temperature, with catalytic efficiency 65%. The recombinant strain reached 31.5% of the total fatty acid, and the conversion rate to AA was up to 77.6%.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: January 14, 2020
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Haiqin Chen, Yongquan Chen, Wei Chen, Tiantian Mei, Zhennan Gu, Hao Zhang
  • Patent number: 10533200
    Abstract: The present invention relates to polynucleotides encoding novel fusion polypeptides essentially composed of a signal peptide for membrane translocation and a polypeptide providing ?-1,6-glucosidase activity and to bacteria containing said polynucleotides. The invention further relates to methods for producing fine chemicals using media containing isomaltose and/or panose as carbon source.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: January 14, 2020
    Assignee: Evonik Degussa GmbH
    Inventors: Kornelia Voss, Michaela Voss, Georg Thierbach